Anthem Biosciences' Q3 FY 2025-26 Quarterly Results
- 06 Feb 2026
Result Summary
- Anthem Biosciences Ltd reported a 23.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 12.5%.
- Its expenses for the quarter were down by 18.4% QoQ and 16.7% YoY.
- The net profit decreased 46.5% QoQ and decreased 25.3% YoY.
- The earnings per share (EPS) of Anthem Biosciences Ltd stood at 1.64 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 456.68 | 598.26 | 522.18 | -23.7% | -12.5% |
Total Expenses | 300.83 | 368.65 | 361.13 | -18.4% | -16.7% |
Profit Before Tax | 130.47 | 229.60 | 161.05 | -43.2% | -19.0% |
Tax | 37.66 | 56.17 | 36.72 | -33.0% | 2.6% |
Profit After Tax | 92.82 | 173.43 | 124.33 | -46.5% | -25.3% |
Earnings Per Share | 1.64 | 3.06 | 0.00 | -46.4% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Anthem Biosciences Ltd is a company that operates in the biosciences industry. While specific details regarding its main products or services are not provided, companies in this sector typically engage in the research, development, and commercialization of pharmaceutical and biotechnological products. Anthem Biosciences Ltd may be involved in activities such as drug discovery, development of biopharmaceuticals, or production of active pharmaceutical ingredients. Recent major developments concerning the company are not available from the provided data.
Revenue
During the third quarter of the fiscal year 2026 (Q3FY26), Anthem Biosciences Ltd reported a total income of ₹456.68 crores. Compared to the previous quarter (Q2FY26), where the total income was ₹598.26 crores, there was a quarter-over-quarter (QoQ) decline of 23.7%. On a year-over-year (YoY) basis, the total income also decreased by 12.5% from ₹522.18 crores in Q3FY25. This reduction in revenue reflects changes in the company's financial performance over the given periods.
Profitability
The profit before tax for Q3FY26 was ₹130.47 crores, which represents a 43.2% decrease from ₹229.60 crores recorded in Q2FY26. When compared to the same quarter in the previous year (Q3FY25), where the profit before tax was ₹161.05 crores, there is a YoY decrease of 19.0%. The tax expense for Q3FY26 was ₹37.66 crores, which is 33.0% lower than the ₹56.17 crores incurred in Q2FY26. The profit after tax for Q3FY26 was ₹92.82 crores, reflecting a significant QoQ decline of 46.5% from ₹173.43 crores in Q2FY26 and a YoY decrease of 25.3% from ₹124.33 crores in Q3FY25. Earnings per share for Q3FY26 were reported at ₹1.64, decreasing by 46.4% from ₹3.06 in the previous quarter.
Operating Metrics
Total expenses for Anthem Biosciences Ltd in Q3FY26 amounted to ₹300.83 crores. This represents an 18.4% decrease from the ₹368.65 crores recorded in Q2FY26. When compared to the same quarter in the previous year, there was a YoY decrease of 16.7% from ₹361.13 crores. The company’s financial performance in terms of expenses indicates a reduction over both the quarter and the year. Earnings per share for Q3FY25 were not reported, making it challenging to assess the YoY percentage change directly from the available data. However, these metrics provide a basis for evaluating the company's operating efficiency over the specified periods.